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ABSTRACT 
The human body has long provided pharmaceutical science with biomaterials of interesting applications. Bile salts (BSs) are 
biomaterials reminiscent of traditional surfactants with peculiar structure and self-assembled topologies. Most of the new drugs, 
biological therapeutics (proteins/peptides) and vaccines have poor performance after oral administration due to poor solubility or 
degradation in the gastrointestinal tract (GIT). Though, vesicular carriers exemplified by liposomes or niosomes can protect the 
entrapped agent to a certain extent from degradation. Nevertheless, the harsh GIT environment i.e, low pH, the presence of bile salts 
and enzymes limits their capabilities by destabilizing them. In response to that, more resistant bile salts-containing vesicles (BS-
vesicles) were developed by the inclusion of bile salts into lipid bilayers constructs. Tremendous research in the last decade has 
made bilosomesa potential carrier system. Bilosomes with its name derived from bile salts (which is one of its major constituents), is 
a ‘niosome-like’ colloidal carrier. Here, we focus on different aspects of bile salt based drug delivery systems including their 
composition, developmental techniques, characterization, comparative advantages of BS-integrated nanomedicines over 
conventional nanocarriers, stability, transitional modifications and scale-up – emphasizing their biomedical potential in oral 
immunization against various diseases and delivery of peptide drugs. Bile acid-based amphiphiles, in the form of mixed 
micelles, bilosomes, drug conjugates and hybrid lipid-polymer nanoparticles are critically discussed as delivery systems for 
anticancer drugs, antimicrobial agents and therapeutic peptides/proteins, including vaccines. Current pitfalls, future perspectives, and 
opinions have also been outlined. Bile acid-based nanoparticles are a growing research area therefore, multifaceted pharmaceutical 
and biomedical applications of bile salts are to be expected in the near future. 
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1. INTRODUCTION 
Human body homeostasis is maintained by numerous 
endogenous substrates characterized by unique 
properties that help them to perform specific functions. 
For years, bile acids were recognized as biosurfactants 
with crucial roles in endogenous organotropism. They 
are facial amphiphiles synthesized in the liver and stored 
in the gall bladder, and exist as ionized bile salts (BSs) 
under physiological conditions. The unique molecular 
structure and interfacial properties of these amphiphilic 
steroidal compounds have made them an intriguing 
subject for pure academic research. Bile acids are facial 
amphiphiles which renders them peculiar surface active 
and interfacial properties, attaining higher surface 
tension values in aqueous solution than classical 
surfactants. The adsorption dynamics is a very fast 
process but despite their strong affinity for the interface, 
bile acids do not reach high surface pressures due to less 
efficient interfacial packing compared to conventional 
amphiphiles. The values for the molecular areas suggest 
that bile acids adopt an almost flat conformation at 
interfaces, with the rigid steroidal backbone parallel to 
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the interface to allow the contact of the hydroxyl groups 
with the aqueous environment, which correlates with 
their facial amphiphilic structure 
1
.  As a consequence of 
their facial amphiphilic nature and the rigid steroid 
backbone, bile acids exhibit a complex self-assembly 
behavior, namely a stepwise aggregation process over a 
broad concentration range that differs from conventional 
surfactants 
2-4
. Their extraordinary emulsifying and 
solubilizing properties have led to their utilization as 
delivery systems for medicines and cosmetics as well 
1,5
. 
In the pharmaceutical field, BSs have been exploited to 
improve hydrophilicity of water-insoluble active 
pharmaceutical ingredients (such as amphotericin B, 
resveratrol, and oxaprozin) mainly by the wetting 
effect
6-8
. Furthermore, BSs have been employed as 
permeation enhancers in topical dosage forms including 
buccal, ocular, nasal, and transdermal routes of 
administration 
9-12
. Besides, the serendipitous discovery 
of BS gelation tendency led to their use as low-
molecular-weight cationic hydrogelators 
13
. A recent era 
in pharmaceutical research encompassed fabrication of 
BS-integrated nanocarriers to overcome major obstacles 
of drug delivery. To improve drug–receptor interactions, 
many new designed potent drug molecules based on 
contemporary drug discovery programs possess high 
degree of lipophilicity that unfortunately causes poor 
solubility in GI fluids accompanied by low and variable 
bioavailability 
14
. Different strategies that include 
encapsulating therapeutic agents or vaccines into nano-
colloidal delivery systems (polymeric or lipid-based 
nanoparticles, nanoemulsions, nanostructured lipid 
carriers, mixed micelles and vesicular structures) have 
been adopted by researchers to cope with impediments 
associated with delivering these challenging agents to 
specific target tissues 
15-19
. Among different classes of 
colloidal systems, vesicular carriers have gained 
particular attention in delivering poorly soluble drugs 
and proteins/ peptides 
20
. Vesicular carriers comprise of 
unilamellar or multilamellar spherical structures formed 
of lipid molecules gathered into bilayers orientation and 
capable of encapsulating drug molecules 
21
. 
Conventional vesicular systems exemplified by 
liposomes and niosomes have demonstrated an 
appealing potential in augmenting the oral 
bioavailability of therapeutic agents and immunogenic 
response of vaccines 
20
. Nevertheless, the efficacy of 
conventional vesicles has been compromised by their 
instability in the GIT, which necessitated modification 
in their bilayers constructs to improve their in vivo 
resistance 
22
 (Table 1). Different research efforts 
conducted over the past decade has demonstrated the 
effectiveness of including bile salts into vesicular 
systems bilayers in improving their in vivo resistance 
and performance after oral administration 
23-24
. 
Accordingly, the aim of this review is to provide a 
comprehensive overview of the fundamentals of bile 
salts-containing vesicles (BS-vesicles) with a focus on 
their successful applications in delivery of drugs, 
therapeutic proteins/peptides and vaccines. 
 
Table 1: A Comparative account of different vesicular systems (liposomes, Niosomes and bilosomes)
25
 
Characterization 
parameter 
Liposomes 
 
Niosomes 
 
Bilosomes 
Composition Phospholipids With 
cholesterol and charge 
inducer 
Nonionic Surfactant with 
cholesterol and charge 
inducer 
Nonionic Surfactant and 
bile salt and charge 
inducer 
Chemical stability Undergo Oxidative 
degradation 
Does Not undergo oxidative 
degradation 
Does not undergo 
oxidative degradation 
Stability in simulated 
gastric ﬂuid 
Unstable Unstable Stable 
 
Stability in simulated 
intestinal ﬂuid 
Unstable 
 
Unstable 
 
Stable 
Antigen dose Relatively high Relatively high Relatively low 
Storage stability Required Liquid nitrogen for 
storage 
Special Conditions not 
required 
Special Conditions not 
required 
 
2. BILE SALT INTEGRATED DELIVERY 
SYSTEMS 
Recently, BSs have been exploited as a core for versatile 
nanosystems. From a review of the literature, major 
categories of BS-integrated nanocarriers can be 
classified as follows. Figure 1 summarizes the four 
major BS- integrated nanosystems. 
2.1.  Size-tunable cholate nanocarriers 
Recently, a unique class of amphiphilic copolymers was 
introduced into the field of cancer targeting and gene 
delivery based on BS core. Such polymers are composed 
of a hydrophilic linear hydrophilic biodegradable branch 
such as PEG [polyethylene glycol], dextran, pullan, 
chitosan, and PLGA [poly (lactic-co-glycolic acid)] and 
a flexible two-arm linear oligomer of cholic acids as a 
hydrophobic core-forming block. Owing to 
hydrophilicity of the surface, such amphiphilic 
structures would spontaneously form self- 
nanoaggregates in water promoted by intra- and/or 
intermolecular association between hydrophobic 
segments to minimize interfacial free energy.
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Figure 1: Diagrammatic representation of four major BS-integrated nanosystems 
26
 
 
Furthermore, the resultant nanocarriers exhibit tunable 
properties owing to the rigidity of the steroidal 
polycyclic backbone and the amphiphilic properties of 
bile acids. Consequently, biodegradable nanocarriers 
based on bile acids are of captivating potential in the 
field of drug delivery. 
27
 
2.2.  Bile salt-phospholipid mixed micelles  
Bile acids can form mixed micelles when combined 
with polar lipids, conventional surfactants or 
amphiphilic drugs, usually with lower CMC and better 
solubilization capacity than the individual components 
due to synergistic interactions. Additionally, mixed 
micellar systems can be prepared without the aid of 
organic solvents and are applied in pharmaceutical 
formulations to improve the bioavailability of poorly 
water soluble drugs 
28-29
. Moreover, phospholipids such 
as lecithin buffer the detergent properties of bile salts 
and attenuate their cytotoxic effects due to mixed 
micelle formation 
30
. A commercial formulation for 
intravenous administration of diazepam, a lipophilic 
benzodiazepine, employs mixed micelles of glycocholic 
acid and soy lecithin as solubilising agent 
30
. The 
antifungal drug amphotericin B, a hydrophobic polyene 
antibiotic, is commercialized as micellar dispersion with 
sodium deoxycholate for parenteral administration. The 
formulation takes advantage of the facial amphiphilic 
nature of both the drug and the bile acid, which 
promotes their association 
28
.  
2.3.  Bile acid-polymer nanocarriers  
Polymeric nanoparticles represent a new generation of 
therapeutic delivery platforms with several advantages 
over lipid-based carriers, such as micelles or liposomes, 
due to their smaller size and higher cell-penetrating 
capacity, showing enhanced circulation time and 
preferential accumulation at the target site via the 
enhanced permeability and retention effect 
31
. In this 
context, lipid-polymer hybrid amphiphiles obtained by 
conjugation of bile acids with hydrophilic and 
biodegradable polymers constitute promising drug 
delivery systems. These hybrid amphiphiles can self-
assemble in aqueous environments to form nano-sized 
micelles with a unique core-shell structure, made of a 
hydrophobic bile salt core stabilized by a hydrophilic 
corona 
26
. The size of both core and corona-forming 
blocks is relevant for drug loading, and higher 
entrapment efficiency of hydrophobic drugs is 
associated with larger cores, whereas the increase in 
polymer length of the hydrophilic corona-forming block 
contributes to increasing the CMC. Some of these 
systems formed micelles with sizes between 10–100 nm, 
which has been reported as the optimum size for passive 
tumor targeting with minimum liver uptake 
26
. The 
solubilization efficiency of PEGylated bile acids was 
found to depend on the nature of the bile acid and on the 
length and number of grafted PEG chains 
32
. Self-
emulsifying drug delivery systems (SEDDSs) based on 
PEGylated bile acids and oleic acid enhanced the 
solubilization and absorption of itraconazole, a poorly 
water-soluble antifungal agent, providing a controlled 
release system with significant improvement of 
itraconazole bioavailability in rats 
33
.  
2.4.  Bile acid-drug conjugates  
Bile acid-drug conjugates act as Trojan horses taking 
advantage of the organotropism of bile acids in the 
enterohepatic circulation for specific drug targeting to 
the liver or to improve metabolic stability and enhance 
intestinal absorption of poorly water soluble drugs 
making use of the bile acid transport systems 
34
. 
Conjugation of therapeutic peptides, proteins and 
oligonucleotides to bile acids increases metabolic 
stability and improves intestinal absorption and systemic 
bioavailability of the macromolecules. Recombinant 
human insulin has been covalently attached to 
deoxycholic acid to obtain orally active insulin 
analogues 
35
. Conjugation of cytotoxic agents with bile 
acids can also improve the pharmacokinetic properties 
of the drug while targeting it to the liver. For example, 
conjugation of cytarabin with cholic acid showed potent 
antitumor activities on cytarabine-sensitive HL60 cells, 
excellent targeting to the liver, good absorption and 
longer half-life in vivo compared to cytarabine alone 
36
. 
 
Size tunable cholate 
nanoparticles 
Bile salt 
+ Hydrophilic 
 
Hydrophobi
c  
Surface engineered 
bilosomes  
Bilosomes 
Mixed micelles 
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2.5.  Bilosomes 
Bilosomes, first described by Conacher et al 
37
, are 
closed bilayer structures of non-ionic amphiphiles 
closely correlated to non-ionic surfactant vesicles 
(niosomes) but incorporating bile salts. Figure 2 shows 
composition with key features of a typical bilosome and 
protection of bilosomes with their contents offered by 
bile salts against the harsh environment of the gut. 
Several research groups have demonstrated the potential 
of utilizing bilosomes in facilitating successful oral 
vaccine delivery 
38-41
. 
 
 
Figure 2: a) Composition and key features of a typical bilosome. (b) Protection of bilosomes and their contents offered 
by bile salts against the harsh environment of the gut. 
25
 
2.5.1. Oral drug candidates  
Amenability of bilosomes for enhancing oral availability 
was not confined to hydrophilic drugs entrapped in 
hydrophilic core.
42
 Few hydrophobic actives have been 
successful candidates for bilosomes as well where the 
drug would be entrapped in the phospholipid (PL) 
bilayer of the vesicles. In this context, Chen et al 
23
 have 
investigated the oral bioavailability of fenofibrate-
loaded bilosomes and conventional liposomes compared 
with the micronized form of the drug. Bioavailability 
from bilosomes was significantly higher than that from 
liposomes and the micronized form. Guan et al. 
43
 
loaded Cyclosporine in bilosomes in comparison with 
conventional liposomes and marketed a microemulsion 
product (Sandimmune® and Neoral® [Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA]). 
Among others, bilosomes exhibited the lowest in vitro 
drug release but the highest oral bioavailability. 
2.5.2. Oral Immunization 
Oral immunization is always preferred over 
conventional immunization achieved through the 
parenteral route because of the associated high 
production costs associated with the need for a sterile 
environment, pain at the site of administration, 
uneasiness to the patient and risk of disease 
transmission. Moreover, oral immunization is 
considered superior because it induces mucosal immune 
response (i.e. induction of sIgA), which is the 
predominant entry site for most of the infectious 
pathogens. 
Bilosomes in oral immunization with model antigen 
Conacher et al. reported oral immunization using BSA 
37
. The orally administered bilosomal formulation 
containing BSA induced high antibody titers against it, 
which were found to be equivalent to those generated 
after systemic immunization. Singh et al. formulated 
BSA-loaded and CTB-conjugated bilosomes to enhance 
their affinity toward M cells of Peyer’s patches 44. 
Bilosomes in oral immunization against influenza 
Conacher et al. reported oral immunization using an 
influenza subunit vaccine and demonstrated that orally 
Rajput et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2017; 7(5):4-16                             
ISSN: 2250-1177                                                                              [8]                                                                            CODEN (USA): JDDTAO 
administered formulation induced high antibody titers 
and cell-mediated response as compared with systemic 
immunization. T helper type 1 and type 2 responses 
were found to be induced 
37
. Mann et al. optimized 
bilosomes containing A/Panama influenza 
hemagglutinin and demonstrated that bilosome-
entrapped influenza HA not only induced significant 
specific systemic antibody production but also mucosal 
IgA. Whereas parenterally administered inactivated 
influenza vaccines resulted in protection from 
homologous viral infection by induction of serum anti-
HA IgG antibodies, they were relatively inefficient in 
protection against variant strains arising during the 
influenza season 
45
. 
Bilosomes in oral immunization against hepatitis B 
Arora et al. reported oral immunization against hepatitis 
B virus using mannosylated bilosomes. Immune 
response was found to be significantly higher along with 
enhanced sIgA level at all local and distal mucosal sites 
as compared with bilosomes alone, whereas parenteral 
vaccine was unsuccessful at providing any considerable 
cell-mediated response 
46
. Shukla et al. reported oral 
delivery of recombinant HBsAg using bilosomes 
40
. 
Bilosomes in oral immunization against tetanus 
Mann et al. reported the significant systemic and 
mucosal immunity on oral immunization with Tetanus 
toxoid-loaded bilosomes 
45
. The Tetanus toxoid 
entrapped in bilosomes was found capable of inducing 
Th2 response characterized by systemic IgG1. A clear 
dose-dependency was observed with specific Tetanus 
toxoid IgG1 antibody titers, which was induced only 
with a higher concentration of Tetanus toxoid (200 
mg/dose), not with the lower one (40 mg/dose). In 
addition to antibody production, only the Tetanus toxoid 
entrapped in bilosomes resulted in SIgA antibodies. The 
endpoint antibody titers were superior to oral 
administration of the un-entrapped antigen, but 
comparable to parenterally delivered Tetanus toxoid. 
Only Th2 and IgA responses were induced with orally 
delivered, entrapped antigen 
47
. 
Bilosomes in oral immunization against diphtheria 
Katare and coworkers developed nano-bilosomes 
containing Diphtheria toxoid prepared by thin film 
hydration that was characterized in vitro for their shape, 
size, percent antigen entrapment and stability and in vivo 
for anti-Diphtheria toxoid IgG and anti-Diphtheria 
toxoid sIgA response in serum and in various body 
secretions, following oral immunization with different 
doses of Diphtheria toxoid entrapped in nano-bilosomes 
41
. The highdose-loaded nano-bilosomes (Diphtheria 
toxoidNB3, 2 Lf) produced comparable anti-Diphtheria 
toxoid IgG levels in serum to those induced by IM-
administered alum-adsorbed Diphtheria toxoid (0.5 Lf). 
All nano-bilosomal formulations elicited a measurable 
anti-Diphtheria toxoid sIgA response in mucosal 
secretions, whereas IM-administered alum-adsorbed 
Diphtheria toxoid (0.5 Lf) was devoid of this response. 
The orally administered nano-bilosomal Diphtheria 
toxoid formulation produced comparable serum 
antibody titers to IM administered alum-adsorbed 
Diphtheria toxoid at a fourfold higher dose and without 
the induction of tolerance. 
2.6.  Nonoral bilosomes 
In a paradoxical effect for oral bilosomes where BS 
content strengthens the wall against digestion, BS-
modified liposomes have been utilized via other routes 
as permeation enhancers due to elasticity. In this 
context, transdermal transferosomes have been 
investigated in numerous research articles for enhancing 
percutaneous drug absorption. Transferosomes are 
ultradeformable liposomes that contain different edge 
activators including BSs 
48
. Transferosomes containing 
BSs demonstrated efficacy in improving transdermal 
permeation of cosmetics and pharmaceutical molecules 
when used in concentrations lower than 0.2% [
49
. 
Sodium cholate demonstrated efficacy as edge activator 
as equal as Tween-80 and Span-80 in improving 
transdermal permeation of estradiol 
50
. The application 
of bilosomes in corneal penetration is a novel field that 
has not so far been fully investigated. Dai et al 
51
 have 
considered elaboration and corneal permeation of 
bilosomes as novel ocular delivery systems for 
tacrolimus. A previous study has indicated that 
liposomes loaded with tacrolimus can facilitate 
penetration of the drug across the cornea into the 
aqueous humor 
51
. However, transcorneal permeation 
from liposomal suspension was still too small to achieve 
a therapeutic effect. Realizing poor corneal permeation 
of drugs and delivery systems, the authors investigated 
ocular tacrolimus bilosomes containing different types 
of BSs as permeation enhancers. 
2.7.  Probilosomes 
Nanocarrier preconcentrates can spontaneously form the 
corresponding liquid-state nanomedicine upon ingestion. 
Because they are deprived of water, self-nanocarriers 
possess higher physical stability compared with liquid 
nanocarriers. Proliposomes are dry, free-flowing 
granular products that instantaneously form 
multilamellar liposomal dispersion upon ingestion. It 
was reported that oral delivery of liposomes could be 
improved by enhancing their ability to retain their 
integrity at the site of absorption, which could be 
achieved by formulating them into proliposomes 
52-53
. In 
this context, Song et al. have developed proliposomes 
using STDC (2.5%, w/w) for the oral delivery of salmon 
calcitonin. They reported a 7.1-fold increase in the 
calcitonin bioavailability from probilosomes. They 
assumed that proliposomes are superior in protecting 
calcitonin against possible degradation by gastric fluid. 
Furthermore, entrapment efficiency and permeation of 
probilosomes were higher compared with the 
proliposomes that could be attributed to the formation of 
a lipophilic ion pair between the drug and BS 
54
. 
2.8.  Surface-engineered bilosomes  
Surface modification of bilosomes has been recently 
proposed in a few research articles attempting to 
increase stability and targeting efficiency of the 
nanovesicles. In the field of oral immunization, surface-
modified vesicles were reported by anchoring a suitable 
ligand for a variety of receptors (such as mannosyl, 
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galactosyl, folic acid and fibronectin) preferentially and 
abundantly present on the cell surface of antigen-
presenting cells in mucosal linings 
55-56
. In this context, 
Jain et al 
57
 developed novel glucomannan-modified 
(GM) bilosomes for eliciting an immune response 
following the oral administration of tetanus toxoid. The 
authors compared three types of vesicular systems, 
niosomes, bilosomes, and GM-bilosomes. All vesicular 
systems exhibited comparable in vitro quality attributes 
(particle size, zeta potential, and entrapment efficiency). 
Nevertheless, GM-bilosomes showed a higher 
immunological response parallel to maintained chemical 
and conformation stability of the tetanus toxoid 
entrapped. Results revealed significant immunological 
superiority of GM-bilosomes to conventional bilosomes 
and superiority of both formulations to niosomes, oral 
and IM peptides. The authors attributed this 
improvement to the polymeric nature of GM that 
increases the surface functionality by increasing 
mannose molecules density on the surface, which can 
enhance the uptake of mannosylated bilosomes by the 
antigen-presenting cells. Furthermore, the polymeric 
nature of GM can also provide stability against digestive 
enzymes. The ability of glucomannosylated bilosomes 
to improve targeting efficiency for oral immunization 
with bovine serum albumin has also been reported 
57
. 
3. PREPARATION OF BS-VESICLES 
Based on the reviewed literature, BS-vesicles were 
prepared using different methods are schematically 
illustrated in Figure 3 
58
. Table 2 shows examples of 
various bilosomes prepared by different methods. 
 
 
Figure 3: Representation of different methods adopted for preparation of bile salts-containing vesicles. (A) Reverse 
phase evaporation method, (B) Thin film hydration method and (C) Hot homogenization method 
58
. 
 
4. IN VITRO CHARACTERIZATIONS AND 
VARIABLES INFLUENCING BS-
VESICLES 
The in vitro characterizations of BS-vesicles included 
determination of the vesicle size, polydispersity index 
(PI), zeta potential, vesicles morphology, entrapment 
efficiency, in vitro release and cellular uptake studies. A 
brief description of the characterization techniques and 
variables influencing some properties of BS-vesicles are 
provided hereafter. Table 3 shows different methods for 
BS-vesicles characterization. 
4.1.  Particle size, PI, Morphology, Zeta potential and 
Entrapment efficiency 
Particle size of BS-vesicles exerts substantial impact on 
their in vitro and in vivo performances 
47
. Regarding the 
influence of bile salts content, substantial decrease in 
particle size and PI of BS-vesicles was associated with 
the increase in bile salt contents due to the enhanced 
flexibility and decrease in surface tension of the vesicles 
23,43,51,61
. However, further increase in bile salts content 
caused vesicles enlargement bound with increase in PI 
due to the increase in medium viscosity 
43
. 
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Table 2: Formulation details and preparation methods of  bile salt-containing liposomes (BS-liposomes). 
Vesicular 
carrier 
Composition Antigen Preparation 
method 
Vesicle size reduction Ref 
BS-
liposomes 
SPC:STC (5:1) Tacrolimus/ Poorly 
water solubility drug 
Thin film hydration 
method 
Ultrasonication 
51 
BS-
liposomes 
SPC:SGC (4:1) Porcine insulin/ 
Protein drug 
Reverse phase 
evaporative method 
High-pressure 
homogenization 
59 
Bilosomes 
 
MPG:CH:DCP (5:4:1) 
100 mM of SDC 
Gonadotropin-
releasing hormone 
immunogen 
Hot 
homogenization 
method 
Homogenization 
60 
BS-
liposomes 
SPC:SDC (4:1) Fenofibrate/ Poorly 
water soluble drug 
Thin film hydration 
method 
Sonication followed 
by high-pressure 
homogenization 
23 
BS-
liposomes 
SPC:SDC (3:1) Cyclosporine A/ 
poorly water soluble 
drug 
Thin film hydration 
method 
High-pressure 
homogenization 
43 
BS-
liposomes 
SPC:bile salts 
(SGC/STC/SDC) (4:1) 
Recombinant human 
insulin/ Protein drug 
Reverse phase 
evaporation 
method 
High-pressure 
homogenization 
24 
Bilosomes  STS:CH:DCP (7:3:1), 
100 mg of SDC 
Diphtheria toxoid Thin film hydration 
method 
Extrusion through 200 
nm pore membrane 
41 
Bilosomes  
 
STS:CH:DCP (7:3:1), 
100 mg of SDC 
Hepatitis B Antigen Thin film hydration  
method 
Extrusion through 200 
nm pore membrane 
40 
 
Bilosomes MPG:CH:DCP (5:4:1), 
100 mg of SDC 
BSA and measles 
peptide 
Thin film hydration 
method 
 
37 
CTB- 
bilosomes  
 
STS:CH:modified 
DPPE  (7:3:1); 100 mg 
of SDC, Conjugation 
of CTB to bilosomes 
Hepatitis B surface 
Antigen 
 
Thin film hydration 
method 
 
Extrusion through 200 
nm pore membrane 
 
38 
GM-
bilosomes  
 
SMO:CH:SDC 
(2:1:0.1) GM-OCM-
DSPE (10% w/w of 
total lipid content) 
Tetanus toxoid 
 
Thin film hydration 
method 
Sonication 
57 
 
The pH of the hydration medium also influences the 
particle size of the vesicles due to the ionization of bile 
salts at higher pH which in turn increase its surface 
activity 
36
. Likewise, different processing variables 
influenced the vesicles particle size. The multilamellar 
micron-size BS-vesicles produced by thin film 
dispersion method were converted into small 
unilamellar nano-sized vesicles using extrusion through 
membrane 
40-41
, ultrasonication 
51
 or homogenization 
43
. 
The preparation method also influences the vesicle 
particle size. Mann et al. 
47
 reported that homogenization 
method produced single population of small vesicles; 
however, thin film method produced a mixture of large 
vesicles combined with smaller ones. It is worth 
mentioning that the uptake of bilosomes by Peyer’s 
patches and mesenteric lymph tissue is somehow 
dependent on the vesicles size 
47
. Bilosomes with size 
between 5 and 10 mm are retained within the Peyer’s 
patches offering mucosal immunoglobulin A (IgA) 
response, whereas particles less than 5 mm are conveyed 
into the efferent lymphatics inside macrophages 
inducing predominantly circulating antibody response. 
Likewise, particle size of BS-liposomes influences their 
in vivo cellular uptake via endocytosis. Niu et al. 
24
 
reported that SGC-liposomes with particle size of 80–
400 nm showed more cellular uptake in comparison to 
their counterpart with size of 2000 nm. Endocytosis is 
an energy dependent process, and the greater extent of 
uptake shown for smaller particle is related to the less 
energy required during the endocytosis process 
24
. 
Transmission electron microscopy was used to ascertain 
the formation of BS-vesicles and visualize their 
morphology 
36
. Zeta potential is the measure of overall 
charges acquired by particles in a particular medium. In 
general, vesicles with surface charge are more stable 
against accumulation than uncharged ones. Opposing 
conventional liposomes that showed a tendency to 
agglomerate, BS-liposomes were negatively charged 
due the presence of bile salts that stimulated the zeta 
potential and hindered the aggregation of the vesicles 
51
. 
Regarding in vivo performance, it is reported that 
negatively charged vesicles are favorably taken up by 
the Peyer’s patches 61.  
For the use of vesicles in pharmaceutical applications, 
one of the most important parameter to assess is the 
entrapment efficiency percent (EE %). It was observed 
that the entrapment of different drugs 
(hexamethylmelamine, Cyclosporine A and fenofibrate) 
increased with the increase in bile salt contents in the 
vesicles. Bile salts, with surface-active properties, can 
integrate perpendicularly into the exterior of the bilayer 
membrane, perturbating the acyl chains of the lipid 
matrix, and thereby increasing the elasticity and 
solubility of drug in the membrane 
23
. However, further 
increase in the content of bile salts simultaneously 
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increases the drug solubility in the dispersion medium, 
thereby compromising the entrapment efficiency 
24
. 
Furthermore, the fluidizing effect of bile salts on the 
lipid bilayers causes leakage of the entrapped drug 
24
. 
The PC content in the vesicles as well contributes to the 
EE. Significant increase in the amount of cyclosporine 
A and hexamethylmelamine entrapped was bound with 
the increase of SPC content, which was attributable to 
the fact that higher lipid content propose more space for 
drug molecules 
43
. The hydration pH affects the EE% as 
its affects the bile salt dissociation, which in turn affects 
the particle size and ability of the bile salts to hold the 
drug molecules 
23-24
. 
4.2.  In vitro release and cellular uptake studies 
Regarding BS-vesicles, the in vitro release study was 
evaluated by dynamic dialysis method to circumvent the 
leakage of vesicles into the external release medium 
24,43,51
. In vitro release studies are essential indicators for 
in vivo performance of a drug delivery system. In 
dynamic dialysis study, compared to conventional 
liposomes, BS-liposomes released more drug due to the 
enhance lipid bilayer fluidity that allowed drug leakage 
from the vesicles 
24
. 
5. IN VIVO PERFORMANCE OF BILE 
SALT VESICLES (BS-VESICLES) 
5.1.  Improvement in oral drug bioavailability 
Based on the published literature, incorporation of drugs 
or proteins into BS-liposomes substantially enhanced 
their bioavailability and in vivo efficacy. It is reported 
that orally administrated SDC-liposomes loaded with 
fenofibrate exhibited 1.57-fold increase in 
bioavailability compared to conventional liposomes in 
beagle dogs 
24
. The observed enhancement was related 
to the uptake of the vesicles through M-cells in the 
Peyer’s patch and facilitated transmembrane absorption 
of fenofibrate due to the ultra-deformability of BS-
liposomes. Likewise, the superiority of BS-liposomes in 
enhancing the oral bioavailability of cyclosporine A 
relative to the marketed microemulsion formulation 
(Sandimmune Neoral) and conventional liposomes was 
confirmed by 
43
. Facilitated absorption of intact BS-
liposomes vesicles rather than enhancing drug solubility 
and release rate was the main reason for the increase in 
cyclosporine A bioavailability. 
5.2.  Enhancement of vaccine immunogenicity 
It is reported that orally administrated bilosomes 
induced cell-mediated responses against synthetic 
peptides and high antibody titers against protein 
antigens comparable to those engendered succeeding 
systemic immunization 
37
. The potential of utilizing 
SDC-bilosomes loaded with either HBsAg or Diphtheria 
toxoid in providing transmucosal immunization was 
investigated by Shukla et al 
40-41
. In both studies, orally 
administrated bilosomes loaded with high dose of 
antigen produced systemic immunoglobulin G (IgG) 
response in mice comparable to those induced by 
intramuscular administrated antigens. In addition, 
bilosomes elicited measurable secretory IgA in mucosal 
secretions that were not induced by IM administrated 
antigens. Similarly, the combinatorial bilosomes 
formulation containing high dose of HBsAg and tetanus 
toxoid, prepared by Shukla et al 
39
, produced anti-
HBsAg-IgG and anti-Tetanus toxoid-IgG levels mice 
serum similar to IM administered HBsAg and Tetanus 
toxoid. Figure 4 shows in vivo performance of orally 
administrated bilosomes depicting confocal laser 
scanning microscopy (CLSM) of the intestine and 
immunological study and measurement of specific IgA 
and IgG 
41
. 
 
Table 3: Major methods for BS-vesicles characterization 
58
 
Characteristics  Methodology References 
Particle size  Dynamic light scattering instrument 
23,37,40 
Laser diffraction particle size analyzer  
54,61 
Polydispersity index  Dynamic light scattering instrument 
57 
Zeta potential  Dynamic light scattering instrument 
51,60,61 
Electrophoretic mobility (EPM) measurements 
57 
Morphology  Transmission electron microscopy (TEM) 
38,40,43,47 
Cryogenic-transmission electron microscopy (Cryo-TEM) 
23 
Scanning electron microscopy (SEM)  
60 
Freeze fracture electron microscopy (FFEM)  
47 
Separation of free drug from drug-loaded 
vesicles 
Molecular exclusion chromatography 
24,40-44,57 
Ultracentrifugation 
37,47,54,60 
Entrapment efficiency percent  High performance liquid chromatography (HPLC) 
23,24,60 
UV spectrophotometer 
43,51 
Bicinchoninic acid (BCA) method 
60 
Micro bicinchoninic acid (MicroBCA) method 
41,57 
Modified ninhydrin assay 
37,45,47 
In vitro release  Dynamic dialysis method 
23,43,51 
Cellular uptake  
 
Human colon adenocarcinoma cell line (Caco-2 cells) 
24,54 
Spontaneously derived human corneal epithelial cells 
51 
Murine macrophage cell line 
57 
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Figure 4: In vivo performance of orally administrated bilosomes. (A) Confocal laser scanning microscopy (CLSM) of 
the intestine and (B) Immunological study and measurement of specific IgA and IgG 
41 
 
6. STABILITY CONSIDERATIONS OF BS-
VESICLES 
Stability studies (whether in-process, in simulated fluids 
or during storage) are of vital prominence for successful 
development of pharmaceutical carrier systems. 
Decomposition of entrapped therapeutic agents may lead 
to decrease in their potency, whereas in the case of 
immunological preparations, denaturation of antigens 
may cause inadequate immune response making the 
subject prone to diseases. 
6.1.  In processing stability 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Different research groups utilized sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
to examine the chemical stability of entrapped peptides 
or antigens in BS-vesicles after being exposed to the 
preparation stress conditions 
28,41,57
. SDS-PAGE is a 
widely used procedure to isolated proteins according to 
their electrophoretic mobility. SDS, as an anionic 
surfactant, was added to protein specimens to linearize 
proteins and impart negative charge thus fractionate 
them according to estimated size through 
electrophoresis. In all the published studies, symmetrical 
position of bands between the pure as well as extracted 
antigens/proteins along with the absence of additional 
bands were evident confirming that the preparation 
method, and the quantity of bile salts included did 
induce any irreversible accumulation or decomposition 
of the entrapped agents. 
6.2.  Storage stability 
Stability studies were carried out to explore the leaching 
of the entrapped agent from the vesicles during storage. 
Shukla et al examined the amount of Diphtheria toxoid 
retained in the bilosomes after storage at refrigerated 
(5±3°C) and room temperature (25±2°C) at 70% relative 
humidity. After one-month storage, around 94% of the 
antigen remained in bilosomes stored at room 
temperature, whereas more than 98% of the antigen was 
found in samples stored at refrigerated conditions. The 
stability of the formulations was credited to the negative 
charge induced by DCP on the bilosomes surface that 
caused electrostatic repulsion preventing fusion and 
aggregation of vesicles upon storage 
41
. 
6.3.  Stability in simulated biological milieu 
It is crucial to interpret the stability of vesicular carriers 
and encapsulated peptides and proteins when confronted 
by gastric pH, bile salts and GI enzymes as the intact 
fraction of the vesicles predominantly influences the 
associated in vivo response. The superiority of 
bilosomes to niosomes, affirmed in terms of their ability 
to protect the loaded antigen in simulated biological 
fluids, was attributed to repulsion between the bile salts 
in the vesicle bilayer and the external bile salts in the 
solution 
35
. In this domain, Conacher et al reported that 
niosomes lost all of their initially entrapped BSA 
content in bile salt concentration of 20 mM in contrast 
to bilosomes that retained 85% of its initial BSA, 
thereby, confirming the stabilizing role of bile salts in 
vesicle constructs
37
. In accordance with the 
aforementioned result, Shukla et al reported that 
bilosomes loaded with either HBsAg or Diphtheria 
toxoid retained considerable amount of entrapped 
antigen during stability studies conducted in simulated 
GIF and bile salts solutions (5mM and 20mM 
concentration) 
40-41
. Following a comparable approach, 
Wilkhu et al examined the changes in antigen load of 
bilosomes-incubated GIF. The initial antigen loaded 
(32%) was retained in gastric media; however, it 
decreased to around 8.5–9.5% when the bilosomes were 
simultaneously transferred to intestinal medium due to 
the degradation of antigen located on the surface of 
bilosomes 
61
. 
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Different authors have compared the stability of BS-
liposomes in simulated GI media in comparison to 
conventional liposomes. Hu et al reported that SGC 
liposomes retained most of the insulin load as compared 
with conventional liposomes in either simulated GI 
fluids (including pancreatin or pepsin) or in ex vivo GI 
fluids obtained from rats. The protective effect was 
credited to the enzyme inhibiting ability of SGC and its 
associated membrane stabilization aptitude 
59
. The 
influence of incorporating different bile salts (SGC, 
STC, SDC) on the integrity of  BS-liposomes against 
different protease enzymes (pepsin, trypsin and a-
chymotrypsin) was tested by Niu et al who further 
affirmed the superiority of SGC in formulating BS-
liposomes due to its enzyme-inhibiting ability compared 
to the other investigated bile salts 
24
. 
7. CYTOTOXICITY OF BS-VESICLES 
Bile salts are reported to cause irritation and toxicity 
when used as penetration enhancers because their 
enhancement effect is somehow bound to damaging the 
intestinal epithelial barrier 
62
. However, some 
researchers have shown that PL can reduce the 
noxiousness of bile salts 
51
. In this domain, Niu et al 
evaluated the cytotoxicity of BS-liposomes in 
concentration range of 0.25– 6.25mmol/L using cell 
growth inhibition assay employing Caco-2 cell 
monolayers 
24
. Although, there was a slight reduction in 
cell viability as the liposomes concentration increased, 
non-significant difference was observed among various 
bile salts (SGC, STC and SDC) used or between 
different concentration after incubation for 4 h. The 
obtained findings implied that BS-liposomes exhibited 
non-significant toxicity toward Caco-2 cells at the 
investigated concentrations. Similarly, Dai et al 
evaluated the toxicity of BS-liposomes prepared using 
SGC, STC and SDC in comparison to conventional 
liposomes on the viability of corneal epithelial cells. 
After incubation for 12 h, at low lipid concentration (54 
mg/mL), the viability of the cells were more than 85% 
for all liposomal formulations; however, at high lipid 
concentration (46 mg/mL), both SGC and STC showed 
low toxicity affirming their suitability for ocular drug 
delivery opposite to SDC-liposomes that had greater 
toxicity to corneal cells 
51
. 
8. TRANSPORTATION OF BILOSOMES TO 
PEYER’S PATCHES (M CELLS) 
The M cells of Peyer’s patches can transport 
macromolecules, particles and microorganisms directly 
into intestinal Peyer’s patches 63. The apical surface of 
M cells differs from intestinal absorptive cells because 
they lack a brush border. M cells also contain a large 
number of endocytic vesicles to uptake and transport 
lumen contents across the epithelial layer 
63-64
. A unique 
feature of M cells is the presence of an intraepithelial 
pocket in which transcytosed particles and 
macromolecules are delivered. The pocket contains 
lymphocytes and a few macrophages, which interact 
with the transported antigen or microorganisms. Thus, 
the transport of soluble and particulate antigen by M 
cells is an important primary step in producing a 
mucosal immune response 
65-66
. Additionally, the 
cellular processes of the M cells, which extend into the 
underlying lymphoid tissue, provide potential contacts 
with resident lymphocytes and dendritic cells 
63,65
. The 
M cells can also secrete IL-1, which indicates that M 
cells could provide co-stimulatory signals, such as 
cytokines and cell surface molecules, to T cells and B 
cells in the microenvironment of Peyer’s patches. Figure 
5 shows schematic representation of the uptake of bile 
salts liposomes by intestinal epithelium after oral 
administration 
25
. 
 
 
Figure 5: Schematic representation of the uptake of bile salts liposomes by intestinal epithelium after oral 
administration. (A) Uptake of the vesicles by M-cells in the Payer’s patch, (B) Transport of the vesicles through the 
paracellular pathway and (C) Transcellular uptake of vesicles through the enterocytes. 
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CLSM studies of transportation of bilosomes to 
GALT 
The CLSM studies by Shukla et al. revealed that, after 
administration of R-123-loaded bilosomes, the localized 
fluorescence in the GALT region was found to be much 
higher as compared with the unentrapped R-123 on oral 
administration 
41
. This study confirmed the efficient 
uptake of bilosomes by the GALT and demonstrated the 
capability of bilosomes for transporting the vaccine 
antigens to the Peyer’s patches containing M cells. 
Bilosomes protected the vaccine antigen during its 
passage through the hostile GIT 
45,47
. The CLSM study 
assured the nano-bilosomes mediated effective uptake of 
vaccine antigens by GALT on oral administration, 
which eventually escorted the comprehensive immune 
response. 
9. TRANSLATIONAL MODIFICATIONS 
AND INDUSTRIAL SCALE-UP OF 
BILOSOMES 
In translational research, from laboratory bench to 
industrial scale-up, it is necessary to optimize the 
manufacturing process to improve efficiency and 
simplify production, giving a more economical end-
product. Bennett et al. tested two simplified production 
methods along with two different storage methods 
(lyophilized and non lyophilized) as well as looking at 
the effect of buffer pH 
67
. The formulations were 
assessed in a murine system for immunogenicity, 
alongside characterization in terms of size and antigen 
entrapment, with the stability of these aspects assessed 
with respect to time. Lyophilized and non lyophilized 3-
step formulations induced significant IgG1, IgG2a and 
IgA titers, with the lyophilized version showing stable 
size and antigen entrapment for up to 9 months. 
10. CURRENT RESTRAINS AND FUTURE 
PERSPECTIVES 
A close examination of the literature accentuates two 
major restraints during bilosomal development. Poor in 
vitro/ in vivo correlation is a common drawback with a 
lack of in vitro method that mimics the actual 
conditions. Regular in vitro release methods lack the 
biological constituents significantly affecting vesicular 
digestion (BSs and enzymes). Using ex vivo permeation 
models and regular cell lines to assess vesicular 
permeability would lack this factor as well. A proposed 
solution would involve employment of the in vitro 
digestion-Caco-2 cell model 
68
. This would encompass 
digestive enzymes and BS content in addition to 
amenability for assessment of depot liposomal 
formulations. Although bilosomes proved to be a 
successful carrier for cationic water-soluble actives, 
sufficient loading of anionic active is still an obstacle 
26
. 
Taking into consideration negative charge and 
hydrophilicity of BSs, incorporation of cationic active 
would hold the BS in the bilayer to exert its membrane-
stabilizing effect. Nevertheless, incorporation of anionic 
hydrophilic drugs would be accompanied by low 
entrapment efficiency and migration of both hydrophilic 
BSs and active to external phase 
9
. 
Based on the reviewed literature, BS-liposomes, not 
only were they capable of enhancing the bioavailability 
of poorly water soluble drugs in animal models but also 
they demonstrated the ability to protect the entrapped 
peptides and proteins after oral administration. 
Moreover, after the first breakthrough of utilizing 
bilosomes for oral vaccines delivering by Conacher et 
al. in 2001, investigations by different research groups 
in BALB/c mice confirmed the usefulness of oral 
bilosomes entrapping antigens in alerting both mucosal 
and systemic immune responses 
37
. In addition, surface 
engineered bilosomes (CTB-bilosomes and GM-
liposomes) prepared via anchoring ligands to the 
bilosomal surface demonstrated the ability of targeting 
the antigens into specific immune cells. The availability 
and low cost of bile acids, which can be easily 
derivatized, turns these chiral templates into attractive 
building blocks for the design of novel drugs and drug 
carrier systems 
69
. 
Realizing the importance of vaccines and their delivery 
challenges, the 21st century has witnessed an enormous 
amount of research work in the domain of vaccine 
development. The development of a needle-free, 
painless, patient-compliant and orally active vaccine 
suitable for mass vaccination campaigns in the 
developing countries is warranted 
25
. Accomplishing this 
objective, however, has been constrained by the fact that 
purified protein antigens usually induce systemic 
nonresponsiveness rather than active immunity by orally 
administered vaccine antigens. Moreover, acid 
degradation in the stomach and poor permeability across 
the gastrointestinal mucosa further limit the uptake of 
antigens by M cells, which is an essential step for an 
immune response. Therefore, the development of an 
effective oral delivery system for mucosal vaccines is a 
significant challenge for the immunologists. In this 
regard, various lipid-based delivery systems including 
bilosomes have been increasingly researched and 
developed for oral immunization. However, more 
research is needed to elucidate the mechanisms of 
selective transport of antigens to the intestinal 
lymphatics by bilosomes, specifically processes at the 
cellular level including digestion, uptake and 
intracellular metabolism. Additionally, delivery of a 
broader range of candidate antigens having different 
physicochemical characteristics and instability in the 
GIT must be tested. Further advanced study of different 
aspects of bilosomes for lymphatic delivery is required 
not only to overcome these issues but also to develop 
more- efficient and smart bilosomal vaccine delivery 
systems for better immunization against different fatal 
diseases. Use of this biocompatible, stable, and highly 
specific carrier for vaccination in the near future would 
contribute to a global countermeasure against infectious 
diseases, and would greatly benefit in the eradication of 
the same 
70
. 
The current challenge that faces the researchers is 
applying the gained knowledge to carry out safe trials in 
human subjects to systematically monitor all parameters 
of the elicited immune response and elucidate the exact 
immune mechanism after oral administration of 
bilosomes 
58
. Besides, the precise mechanisms of 
facilitated absorption and the interaction between the 
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BS-liposomes and biological environment have not yet 
been explained due to the complexity of the GI 
physiology. Nevertheless, it is of remarkable 
significance to explicate the exact underlying 
mechanisms of improved absorption of macromolecules 
by BS-liposomes to serve as basis for their optimization. 
Further studies should also include the assessment of the 
influence of the ingested food on the in vivo 
performance of BS-vesicles. 
In addition to the aforementioned, certain criteria must 
be fulfilled in BS-vesicles to ensure their acceptance as 
pharmaceutical carriers. An efficient and adequate 
process for large industrial scale production that ensures 
high and reproducible levels of protein/peptide 
entrapment should be addressed. Furthermore, the long-
term storage stability of BS-vesicles should be 
scrutinized in details, which is still yet far from being 
accomplished due to the limited researches that address 
long-term stability. 
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